Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 4, 2025
10 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 4, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
Reduced
Compared with the manager's Q1 2025 13F
608,517
494,539
−18.7%
Share count drives classification; reported value also moves with price
0.28%
Within the filing's reported positions, not the manager's total assets
10
For Q2 2025
Allene M. Diaz (Director) sold ~$61K of Ionis Pharmaceuticals
Planned saleC Frank Bennett (EVP, Chief Scientific Officer) sold ~$440K of Ionis Pharmaceuticals
Planned saleFund moves
4 tracked managers disclosed the same change for Q2 2025. From a 13F filed Aug 14, 2025 covering holdings at Jun 30, 2025 — a quarter-end snapshot, not a live trade.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.